Reimbursed Care Access in Iran

Currently classified as a strictly controlled substance under Iran’s drug control framework, with no authorized medical use outside of approved clinical research. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research.

There is no publicly available evidence of national regulatory approval or routine reimbursement for intranasal esketamine (Spravato) in Iran; licensed esketamine programs (as exist in some countries) are not documented in Iranian regulatory listings or medical literature. In contrast, esketamine (Spravato) is a regulated, approved product in jurisdictions where it received marketing authorization (example: U.S. FDA listing for context) #. Given the lack of documented approval pathways or published Iranian regulatory authorizations, esketamine should be considered unavailable for routine clinical use or reimbursement in Iran and would only be accessible if explicitly permitted through a formal import/compassionate-use regulatory channel (none publicly documented).

Ketamine is a licensed and commonly used anesthetic and analgesic agent within Iran’s hospitals and clinical practice (used for general anesthesia, procedural sedation, peri‑operative analgesia and documented in randomized clinical trials and procedural-sedation literature). Multiple Iranian clinical trials and systematic reviews show active perioperative and emergency medicine use of ketamine in Iranian hospitals and university settings, demonstrating it is an accepted part of standard medical practice. #; #; #.

Regulatory & reimbursement context: Ketamine’s established role in anesthesia and acute care means it is procured and supplied through hospital pharmaceutical channels and used under specialist supervision; reimbursement for standard anesthetic/operative uses is handled through existing hospital financing mechanisms (public hospitals, university medical centers, and private hospitals) consistent with other licensed anesthetics. There is no clear, country‑wide published policy documenting routine public insurance reimbursement for ketamine when used off‑label for psychiatric indications (e.g., repeated intravenous ketamine for treatment‑resistant depression); such off‑label psychiatric uses, where they occur, are typically organized through private clinics or academic research and would generally not be covered by standard public insurance absent explicit Ministry of Health guidance or a formal national reimbursement decision. Iranian clinical literature does report research and clinical investigations of ketamine for psychiatric endpoints, indicating off‑label clinical/research use exists but without documented universal reimbursement. #; #.

Regional/state nuance: Iran’s health system is centralized; drug licensing and formal reimbursement decisions are made at national level (Ministry of Health / Food and Drug Organization) rather than by subnational states. Hospital-by-hospital practice variation exists (university hospitals and private clinics may run ketamine programs differently), but there is no public record of regional legal permissiveness for otherwise controlled psychedelics.

Practical takeaway: Ketamine is available and routinely used in Iranian medical settings for anesthesia and acute care, and is used in research/off‑label psychiatric contexts, but there is no documented national reimbursement program for ketamine when used specifically as an approved psychiatric therapy (e.g., repeated IV ketamine or intranasal esketamine pathways).

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research.

Currently classified as a strictly controlled substance under national drug scheduling laws (DMT-containing brews are treated as controlled), with no authorized medical use outside of approved clinical research. Domestic reports note virtually no legal or cultural tolerance for ayahuasca and any importation or preparation would be subject to Iran’s narcotics enforcement.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research.